← 返回

在大 B 细胞淋巴瘤中选择最佳治疗方法并优化序贯策略

英文原题:Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.

查看英文原题

Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.

PubMed 2025/12/05(内容时间) Hematology Am Soc Hematol Educ Program Q1 · IF 3.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

T细胞重定向策略的出现,包括CAR-T 细胞和双特异性抗体,显著改善了复发/难治性大B细胞淋巴瘤患者的预后。当前正在进行的临床试验正在探索其在更早期治疗线中的作用,迅速重塑该疾病的治疗格局。该领域已从适合移植的概念转变为适合CAR-T 细胞的概念,尽管当前试验仍考虑前者来定义目标患者人群。在此,我们讨论2个临床病例,以有意说明T细胞重定向策略的这一动态时代,突出主要学习要点,同时也呈现未来需要解决的机会和未解问题。

展开英文摘要原文

The advent of T-cell redirecting strategies, including chimeric antigen receptor T cells and bispecific antibodies, has significantly improved the prognosis of patients with relapsed/refractory large B-cell lymphoma.

Current, ongoing clinical trials are exploring their role in earlier treatment lines, rapidly reshaping the treatment landscape of this disease entity. The field has shifted from the concept of transplant-eligible to chimeric antigen receptor T-cell eligible, albeit current trials still consider the former to define the target patient population.

Here, we discuss 2 clinical cases to deliberately illustrate this dynamic era of T-cell redirecting strategies, highlighting the main learning points but also presenting the opportunities and open questions to be addressed in the future.

论文信息

作者
Iacoboni G、Morschhauser F
第一作者单位
Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.Spain
通讯作者单位
CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, University of Lille, Lille, France.France
文献类型
病例报告
期刊
Hematology. American Society of Hematology. Education Program2025 Dec 5
原文标识
PubMed 41347969 · DOI 10.1182/hematology.2025000740